Get the Stockscreener App
1.01
1.00%
0.01
After Hours:
1.01
Tevogen Bio Holdings Inc stock is traded at $1.01, with a volume of 736.98K.
It is up +1.00% in the last 24 hours and down -20.47% over the past month.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes ("CD8+ CTLs" or "CTLs"), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
See More
Previous Close:
$1.00
Open:
$1
24h Volume:
736.98K
Relative Volume:
0.40
Market Cap:
$176.80M
Revenue:
-
Net Income/Loss:
$52.50M
P/E Ratio:
34.71
EPS:
0.0291
Net Cash Flow:
$-4.13M
1W Performance:
-15.83%
1M Performance:
-20.47%
6M Performance:
+262.01%
1Y Performance:
-70.29%
1-Day Range:
$0.89
$1.02
1-Week Range:
$0.89
$1.18
52-Week Range:
$0.2556
$3.44
Tevogen Bio Holdings Inc Stock (TVGN) Company Profile
Name
Tevogen Bio Holdings Inc
Sector
Industry
Phone
646-807-8832
Address
15 INDEPENDENCE BOULEVARD, SUITE 410, WARREN
Compare TVGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TVGN
Tevogen Bio Holdings Inc
|
1.01 | 176.80M | 0 | 52.50M | -4.13M | 0.0291 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Tevogen Bio Holdings Inc Stock (TVGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-04-25 | Initiated | D. Boral Capital | Buy |
Tevogen Bio Holdings Inc Stock (TVGN) Latest News
Tevogen Bio Holdings Inc. SEC 10-K Report - TradingView
Tevogen Bio Holdings Delays Annual Report Filing - TipRanks
Thomas Butler steps down as Biomea CEO - biocentury.com
Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast - The Manila Times
Tevogen Bio's Ambitious $2B Revenue Target Backed by Leadership Excellence and Key Hire - Stock Titan
Tevogen Bio appoints new head of government affairs By Investing.com - Investing.com South Africa
Tevogen Bio appoints new head of government affairs - Investing.com
Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan - Quantisnow
Tevogen Bio Appoints David E. Banko as Global Head of - GlobeNewswire
Healthcare Access Expert Joins Tevogen Bio to Accelerate Multi-Therapeutic Commercial Launch - Stock Titan
TSX Continues Higher as U.S. Trade Policy Appears to Soften - The Globe and Mail
SPY ETF News, 3/21/2025 - The Globe and Mail
Meta Stock Dips Below $600: A Buying Opportunity or a Red Flag? - The Globe and Mail
Tevogen Bio CEO reinforces commitment to retention of equity capital - MSN
Tevogen Bio’s chief scientific officer sells $253,935 in stock By Investing.com - Investing.com Australia
Tevogen bio’s chief scientific officer sells $253,935 in stock By Investing.com - Investing.com Australia
Tevogen Bio’s chief scientific officer sells $253,935 in stock - Investing.com India
Tevogen bio’s chief scientific officer sells $253,935 in stock - Investing.com
Tevogen Bio Holdings Officer Sells Shares to Cover Tax Obligations - TradingView
Tevogen Bio Holdings Inc. (NASDAQ:TVGNW) Short Interest Down 86.7% in February - Defense World
Tevogen Bio (NASDAQ:TVGN) Receives “Buy” Rating from D. Boral Capital - Defense World
Public market insider selling at Aura Minerals (ORA) - The Globe and Mail
Tevogen bio’s chief scientific officer sells shares worth $231,734 By Investing.com - Investing.com South Africa
Tevogen bio’s chief scientific officer sells shares worth $231,734 - Investing.com India
Tevogen Bio Files New US Patent for T Cell Vaccine Under Development -March 10, 2025 at 01:19 pm EDT - Marketscreener.com
Tevogen announces new patent filed for T cell vaccine - TipRanks
Tevogen Bio Announces Unique T Cell Vaccine Under Development & Files Patent With USPTO - Marketscreener.com
Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO - The Manila Times
Tevogen Bio Files Patent for Innovative T Cell Vaccine Targeting Entire Viral Genome to Combat Mutations - Nasdaq
Tevogen Bio Files Patent for AI-Powered T Cell Vaccine with Military Applications - StockTitan
Have Tevogen Bio Holdings Insiders Been Selling Stock? - simplywall.st
Tevogen Bio Holdings Inc. (TVGN) Secures $8M Grant, Accelerates AI Initiatives with Microsoft - Insider Monkey
Tevogen bio’s chief scientific officer sells shares totaling $250k By Investing.com - Investing.com South Africa
Tevogen Bio's CIO Mittul Mehta Discusses AI Innovations in Biotech at Proskauer Panel - Nasdaq
Tevogen Bio’s CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer’s AI Discussion Panel - GlobeNewswire
Can AI Transform Biotech? Tevogen's Tech Chief Reveals Next-Gen Strategy - StockTitan
Tevogen Bio’S CIO & Head Of Tevogen.AI, Mittul Mehta, Featured Speaker At Proskauer’S AI Discussion Panel - MENAFN.COM
Tevogen bio’s chief scientific officer sells shares totaling $250k - Investing.com
9 AI News Updates Investors Should Not Miss - Insider Monkey
D. Boral Capital Begins Coverage on Tevogen Bio (NASDAQ:TVGN) - Defense World
Analyzing Tevogen Bio (NASDAQ:TVGN) and Qiagen (NYSE:QGEN) - Defense World
Tevogen Bio's T-Cell Therapy Approach Stands Out, Analyst Sees Strong Potential - Benzinga
This Tevogen Bio Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga India
Tevogen initiated with a Buy at D. Boral Capital - TipRanks
Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations - GlobeNewswire
Tevogen Bio To Receive $8 Mln Of Non-Dilutive Grant Funding - MarketScreener
Tevogen Bio Secures Additional $8 Million Grant from KRHP LLC to Advance AI-Driven Immunotherapy Developments - Nasdaq
How Tevogen Bio's $8M Grant Funding Strengthens Its AI-Powered Biotech Future - StockTitan
Tevogen Bio Holdings Inc Stock (TVGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tevogen Bio Holdings Inc Stock (TVGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Flomenberg Neal | See Remarks |
Mar 07 '25 |
Sale |
1.14 |
71,273 |
81,251 |
3,969,212 |
| Flomenberg Neal | See Remarks |
Mar 10 '25 |
Sale |
1.09 |
70,384 |
76,719 |
3,898,828 |
| Flomenberg Neal | See Remarks |
Mar 11 '25 |
Sale |
1.05 |
70,252 |
73,765 |
3,828,576 |
| Flomenberg Neal | See Remarks |
Mar 05 '25 |
Sale |
1.21 |
110,659 |
133,897 |
4,129,004 |
| Flomenberg Neal | See Remarks |
Mar 06 '25 |
Sale |
1.10 |
88,519 |
97,371 |
4,040,485 |
| Flomenberg Neal | See Remarks |
Mar 04 '25 |
Sale |
1.28 |
14,639 |
18,738 |
4,239,663 |
| Flomenberg Neal | See Remarks |
Oct 17 '24 |
Sale |
1.62 |
1,078,600 |
1,747,332 |
4,254,302 |
| Desai Kirti | Chief Financial Officer |
Jun 12 '24 |
Buy |
0.82 |
3,000 |
2,460 |
9,699,186 |
| Saadi Ryan H. | Chief Executive Officer |
Jun 05 '24 |
Buy |
0.77 |
2,607 |
2,000 |
118,252,659 |
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):